Section Editors Robert C. Bast, Jr., MD
Translational Research
UT MD Anderson Cancer Center
Houston, Texas Tracy T. Batchelor, MD, MPH
Neuro-oncology
Brigham and Women's Hospital
Boston, Massachusetts Smita Bhatia, MD, MPH
Outcomes Research
Survivorship
University of Alabama at Birmingham
Birmingham, Alabama Jeremy J. Erasmus, MBBCh
Diagnostic Imaging
UT MD Anderson Cancer Center
Houston, Texas Robert L. Ferris, MD, PhD
Endocrine Disease
Head and Neck Disease
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania Elise Kohn, MD
Gynecologic Oncology
National Institutes of Health
Bethesda, Maryland Sagar Lonial, MD
Hematologic Malignancies
Emory University School of Medicine
Atlanta, Georgia María Elena Martínez, MPH, PhD
Epidemiology
University of California, San Diego
La Jolla, California Viraj Master, MD, PhD
Genitourinary Disease
Emory University School of Medicine
Atlanta, Georgia | Andrew H. Miller, MD
Psychosocial Oncology
Emory University School of Medicine
Atlanta, Georgia Kelvin A. Moses, MD, PhD
Disparities Research
Vanderbilt University Medical Center
Nashville, Tennessee Susan O'Brien, MD
Hematologic Malignancies
University of California, Irvine
Orange, California Ruth O'Regan, MD
Breast Disease
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin Electra D. Paskett, PhD, MPH
Cancer Prevention
Epidemiology
The Ohio State University
Columbus, Ohio Mitchell C. Posner, MD
Gastrointestinal Disease
The University of Chicago Medicine
Chicago, Illinois Suresh S. Ramalingam, MD
Chest and Lung Disease
Clinical Trials
Medical Oncology
Emory University School of Medicine
Atlanta, Georgia Chandrajit Raut, MD
Soft Tissue and Bone Sarcoma
Brigham and Women's Hospital
Boston, Massachusetts | Carlos Rodriguez-Galindo, MD
Pediatric Oncology
St. Jude Children’s Research Hospital
Memphis, Tennessee Walter M. Stadler, MD
Genitourinary Disease
The University of Chicago Medical Center
Chicago, Illinois Kenneth K. Tanabe, MD
Hepatobiliary Tract
Massachusetts General Hospital
Boston, Massachusetts Hussein Tawbi, MD, PhD
Melanoma and Skin
UT MD Anderson Cancer Center
Houston, Texas Lynne I. Wagner, PhD
Symptom Control and Palliative Care
Wake Forest University Health Sciences
Winston-Salem, North Carolina Christopher G. Willett, MD
Radiation Oncology
Duke University Medical Center
Durham, North Carolina Statistical Reviewers Elizabeth Garrett-Mayer, PhD Shing Lee, PhD Mary E. Putt, PhD, ScD Yu Shyr, PhD Mourad Tighiouart, PhD Hao Wang, PhD Guest Section Editor Harry B. Burke, MD, PhD
Safety and Quality
Editorial Staff Esmeralda Galán Buchanan, Senior Director, Journals and Books Publishing
Carissa A. Gilman, Managing Editor
Zachary Beasley, Assistant Managing Editor
Jasmine Coole, Senior Editorial Assistant | | |
Dr. Bast receives royalties from Fujirebio Diagnostics for CA 125. He has no other financial relationships or interests to disclose. Dr. Batchelor serves as a consultant for Champions Biotechnology, Merck & Co., Inc., Proximagen/Upsher, Roche, Oxigene, Cavion, Foundation Medicine, and Accerta. He receives research support from Pfizer. He has provided CME lectures/material for Up to Date, Inc., Oakstone Medical Publishing, and Imedex. He has no other financial relationships or interests to disclose. Dr. Bhatia has no financial relationships or interests to disclose. Dr. Curley has no financial relationships or interests to disclose. Dr. Erasmus has no financial relationships or interests to disclose. Dr. Ferris has served on the advisory boards of Merck, Celgene, Bristol-Myers Squibb, and AZ/MedImmune. He has received grants/research funding from Bristol-Myers Squibb, AZ/MedImmune, and VentiRx. He has no other financial relationships or interests to disclose. Dr. Halpern has served as a symposium speaker for WebMD and has participated in CME program development for Clinical Care Options. He receives research funding from AbbVie and has consulted for Solstice HealthCommunications. He has no other financial relationships or interests to disclose. Dr. Khuri has no financial relationships or interests to disclose. Dr. Kohn has no financial relationships or interests to disclose. Dr. Lonial serves on the scientific advisory boards for Millennium, Celgene, Novartis, Bristol-Myers Squibb, Onyx, and Janssen (he provides guidance on development strategies). He has no other financial relationships or interests to disclose. Dr. Margolin has consulted for Lion, Amgen, and Pfizer, and receives research funding from Amgen, Altor, Bristol-Myers Squibb, and Genentech. She provides intermittent review of clinical trial projects for ImaginAb. She has also received honoraria from Bristol-Myers Squibb for a series of talks given in Australia. She has no other financial relationships or interests to disclose. Dr. Master has provided expert testimony in 2 malpractice cases over the last 11 years. He has no other financial relationships or interests to disclose. Dr. Miller has no financial relationships or interests to disclose. Dr. O’Brien serves as a consultant for Abbvie, Alexion, Amgen, Aptose Biosciences Inc., Astellas, Celgene, Gilead, GlaxoSmithKline, Janssen Oncology, Pfizer, Pharmacyclics, Sunesis, TG Therapeutics, and Vanian Group LLC. She receives research support from Acerta, Gilead, Pfizer, Pharmacyclics, ProNAI, Regeneron, and TG Therapeutics. She has no other financial relationships or interests to disclose. Dr. O’Regan serves as an advisor for Pfizer, Lilly, Eisai, and BioTheranostics. She receives research support from Novartis, Pfizer, and Eisai. Dr. Paskett reviews grants for CPRIT, receives study funding from Merck, and serves on numerous advisory boards for cancer centers. She has no other financial relationships or interests to disclose. Dr. Ramalingam has served on scientific advisory boards for AstraZeneca, Ariad, Amgen, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Novartis, Merck, Lilly, and Genentech. He has no other financial relationships or interests to disclose. Dr. Raut is an author on 5 sections for UpToDate (all sarcoma-related). He has no other financial relationships or interests to disclose. Dr. Rodriguez-Galindo previously served as a Member of the Data Safety and Monitoring Board for Novimmune’s NI-501 trial. He has no other financial relationships or interests to disclose. Dr. Stadler serves as an ad hoc editor for UpToDate. He provides consulting/drug development for AstraZeneca, Caremark/CVS, Eisai, SOTIO, Genentech, and Pfizer. He serves as a CME speaker for Imedex, CME Network, Dava Oncology, Oncology Meeting Innovations, PVI, and Research-to-Practice. He has no other financial relationships or interests to disclose. Dr. Tanabe serves as an associate editor for UpToDate (section editor, gastrointestinal malignancies) and a consultant for Best Doctors, LEK Consulting and Back Bay Life Science Advisors. He also serves as a board member for Helix 12. He also is a patent holder for EGF SNP genotyping for risk of hepatocellular carcinoma, and use of EGFR inhibitors to treat cirrhosis and prevent hepatocellular carcinoma. He receives grant support from the National Institutes of Health, and an honorarium for serving on a review panel for the Congressional Directed Medical research Program. He has no other financial relationships or interests to disclose. Dr. Wagner serves as a consultant for EveryFit, Inc. (research consulting on an NCI SBIR-funded project in health information technology, wearable devices), Celgene, and Janssen (research consulting on patient-reported outcomes in oncology). She has no other financial relationships or interests to disclose. Dr. Willett edits a CME course for Oakstone. He has no other financial relationships or interests to disclose. EDITORIAL BOARD E. Jason Abel, MD
Ghassan K. Abou-Alfa, MD
Saro Armenian, DO, MPH
Isabel C. Arrillaga-Romany, MD, PhD
Chunxue Bai, MD, PhD
Joseph E. Bauer, PhD
Eric H. Bernicker, MD
Harry B. Burke, MD, PhD
Betty Caan, DrPH
Amy Y. Chen, MD, MPH
Edwin Choy, MD, PhD
Christopher H. Crane, MD
Anthony V. D’Amico, MD, PhD
Adil Daud, MD
Linda Duska, MD
Bassell El-Rayes, MD
Nagi S. El Saghir, MD
Carole Fakhry, MD, MPH
Michael J. Fisch, MD, MPH
Bryan C. Fuchs, PhD
Ian Ganly, MD, PhD
Theresa W. Gillespie, PhD, MA, BSN
Sharon H. Giordano, MD, MPH
Jorge Gomez, MD
Patrick Ha, MD | Matthew D. Hellmann, MD
Valérie Jooste, PhD
Virginia Kaklamani, MD, DSc
Kevin Kalinsky, MD, MS
Hagop M. Kantarjian, MD
Jose A. Karam, MD
Wui-Jin Koh, MD
Jonathan A. Ledermann, MD
J. Rebecca Liu, MD
Heather L. McArthur, MD
William M. Mendenhall, MD
Matthew Milowsky, MD
Luc G. T. Morris, MD, MSc
Ronald E. Myers, DSW, PhD
Seigo Nakamura, MD, PhD
Joel W. Neal, MD, PhD | Akinyemi I. Ojesina, MD, PhD
Taofeek K. Owonikoko, MD, PhD
Athanasios G. Papavassiliou, MD, PhD
Keunchil Park, MD, PhD
Elizabeth R. Plimack, MD, MS
Blase N. Polite, MD, MPP
James W. Rocco, MD, PhD
Nabil F. Saba, MD
John M. Salsman, PhD
Clare Scott, MBBS, PhD
Sonali M. Smith, MD
Silvia Stacchiotti, MD
Thomas E. Stinchcombe, MD
Erich Sturgis, MD, MPH
Jennifer S. Temel, MD
Sarah M. Temkin, MD
Mary Beth Terry, PhD
Amye Tevaarwerk, MD
Arafat Tfayli, MD
Benjamin Toll, PhD
Christine Walsh, MD
Wolfgang Wick, MD
Kari B. Wisinski, MD
Christina Wu, MD
Jennifer Yu, MD, PhD
Gelareh Zadeh, MD, PhD |
Dr. Abou-Alfa’s receives research grant support to his institution from Abbott Laboratories, Amgen, Bayer, CASI, Celgene, Eli Lilly and Company/Imclone, Exelixis, Genentech, Immunomedics, Incyte, Momenta Pharmaceuticals, Myriad Genetics, Novartis, OncoMed Pharmaceuticals, Polaris Pharmaceuticals, Roche, and Vicus Therapeutics. He provides consulting services for Aduro Biotech, Array, Astellas Pharma US, BioAlliance, Boston Scientific, Boston Therapeutics, BMS, CASI, Celgene, Cipla, Eli Lilly and Company, EMD Sorono, Gilead, IntegraGen, Medergy, MedImmune, Merrimack, Momenta, Novartis, Onxeo, Pharmacyclics, Sanofi-aventis, Silenseed, Sillajen, and Vicus Therapeutics. He also serves as a speaker for Celgene. He has no other financial relationships or interests to disclose. Dr. Armenian has no financial relationships or interests to disclose. Dr. Bai has no financial relationships or interests to disclose. Dr. Bauer has no financial relationships or interests to disclose. Dr. Brewster has no financial relationships or interests to disclose. Dr. Burke has no financial relationships or interests to disclose. Dr. Caan is the Vice President of Zero Breast Cancer, an organization that propagates and disseminates scientific research on environmental risk factors and lifestyle variables that influence breast cancers. She has no other financial relationships or interests to disclose. Dr. Chapman serves on the advisory boards for LICR Research LTD, Merck, and Rgenix and also serves as a consultant for Scancell, Roche, and Rgenix. He has no other financial relationships or interests to disclose. Dr. Chen has no financial relationships or interests to disclose. Dr. Cooperberg serves as a consultant for Myriad Genetics (research support to department), is co-chair of a registry project for Dendreon and Astellas, and is an advisory board participant for Janssen. He has no other financial relationships or interests to disclose. Dr. Covens owns stock in Novadaq, is a speaker for AstraZeneca, and is the recipient of an educational grant from Roche Canada. He has no other financial relationships or interests to disclose. Dr. Crane has no financial relationships or interests to disclose. Dr. D’Amico has no financial relationships or interests to disclose. Dr. Duska serves on the advisory board for Genentech and as a clinical reviewer for Parexel, a company that provides independent blinded reviews of clinical trials (both radiology and clinical reviews). She consults for ClearView Healthcare Partners and Advance Medical Inc., and has received funding from Millennium and GSK. She has no other financial relationships or interests to disclose. Dr. El-Rayes serves as the principal Investigator on clinical research trials for AVEO Pharmaceuticals, Genentech, Synta, Novartis, Pfizer, Hoosier Cancer Research Network, Boston Biomedical Inc., Cleave Biosciences, Taiho, and Bristol-Myers Squibb, as well co-investigator on clinical trials for NIH and NCI. He has also served on advisory boards for Genentech and Merrimack Pharmaceuticals. He has no other financial relationships or interests to disclose. Dr. Euhus has no financial relationships or interests to disclose. Dr. Fisch owns Anthem stock as part of his compensation from his employer, a subsidiary of Anthem. He has no other financial relationships or interests to disclose. Dr. Fuchs serves as a paid consultant for Collagen Medical (advice management regarding the development of a molecular MR probe for detecting fibrosis), a speaker for Merck on noninvasive imaging of fibrosis at the Boston Fibrosis Symposium, and a speaker for Enanta Pharmaceuticals on animal models of fibrosis. He has received research support from Nimbus Therapeutics to investigate ACC inhibitors for treatment of HCC and from Enanta Pharmaceuticals to investigate FXR agonists as a treatment for liver fibrosis. He has no other financial relationships or interests to disclose. Dr. Gadgeel serves on the advisory boards for Pfizer, Roche, ARIAD, Novartis, AstraZeneca, and Boehringer Ingelheim. He has no other financial relationships or interests to disclose. Dr. Ganly has no financial relationships or interests to disclose. Dr. Garrett-Mayer serves as a consultant for Tactical Therapeutics and Okava Pharmaceuticals (provides design and statistics advice). She has no other financial relationships or interests to disclose. Dr. Gillespie has no financial relationships or interests to disclose. Dr. Giordano has no financial relationships or interests to disclose. Dr. Ha serves as consultant for Bristol-Myers Squibb and has done some defendant malpractice/legal case review. He has no other financial relationships or interests to disclose. Dr. Hurteau has no financial relationships or interests to disclose. Dr. Jooste has no financial relationships or interests to disclose. Dr. Kaklamani serves as a consultant/speakers bureau member for Eisai, Celgene, Genentech, and Genomic Health. She has no other financial relationships or interests to disclose. Dr. Kantarjian has no financial relationships or interests to disclose. Dr. Ledermann serves on the advisory boards/trial steering groups for AstraZeneca, Pfizer, Clovis, and Merck/MSD. He has also given lectures/symposia for AstraZeneca and Roche. He has no other financial relationships or interests to disclose. Dr. Lerner serves as consultant for BioCancell, Vaxiion, UroGen, and Telesta Therapeutics, as well as an expert advisor for Sitka Biopharma, Nucleix, TARIS Biomedical, and Ferring. He has received grants/research support from Endo, FKD Therapies, Viventia Bio, Roche/Genentech, and GenomeDx. He has no other financial relationships or interests to disclose. Dr. Liu has no financial relationships or interests to disclose. Dr. Lonial serves on the scientific advisory boards for Millennium, Celgene, Novartis, Bristol-Myers Squibb, Onyx, and Janssen (he provides guidance on development strategies). He has no other financial relationships or interests to disclose. Dr. Maki serves as a consultant for Bayer, Arcus Biosciences, Novartis, Eisai, Lilly, Gem Pharmaceuticals, Presage Biosciences, Pharmamar, Janssen, Epizyme, Karyopharm Therapeutics, Trillium Therapeutics, and Taiho Pharmaceutical (advises on clinical trials and options for therapy within sarcoma and phase I spaces). He has no other financial relationships or interests to disclose. Dr. Mendenhall has no financial relationships or interests to disclose. Dr. Mendez has no financial relationships or interests to disclose. Dr. Milowsky receives pharmaceutical money to his institution for clinical trials. He has no other financial relationships or interests to disclose. Dr. L. Morris has no financial relationships or interests to disclose. Dr. M. Morris serves as a consultant for Millennium and Tokai Pharmaceuticals (compensated) and Bayer and Astellas (not compensated). He has also received travel to meetings from Bayer. He has no other financial relationships or interests to disclose. Dr. Myers has no financial relationships or interests to disclose. Dr. Omuro serves on the advisory boards for Juno Therapeutics, Stemline Therapeutics, and Bristol-Myers Squibb. He has no other financial relationships or interests to disclose. Dr. Owonikoko serves as a consultant for Novartis, Sandoz, Lilly, and Medivation. He has no other financial relationships or interests to disclose. Dr. Polite serves as a consultant for AstraZeneca (drug pricing strategies), Pfizer (biosimilar policy), and GLG Consulting (various consulting primarily with investment community regarding colorectal and neuroendocrine cancer). He has no other financial relationships or interests to disclose. Dr. Powell serves on the advisory boards for Genentech (consultant on educational programs for pulmonary physicians) and Siemens. He has no other financial relationships or interests to disclose. Dr. Putt owns stock in Eli Lilly, Pfizer, Johnson & Johnson, Merck & Co, Roche, Siemens, Novartis, and Bayer. She has no other financial relationships or interests to disclose. Dr. Redman serves as an advisor for Takeda (on independent data safety monitoring board) and Ignyta (on data safety monitoring board). She has no other financial relationships or interests to disclose. Dr. Saba serves as an advisor for Merck, Bristol-Myers Squibb, and Pfizer. He has no other financial relationships or interests to disclose. Dr. Shah has no financial relationships or interests to disclose. Dr. Shih serves on the advisory boards for Novartis and Genentech (advises on clinical care of lung cancer patients with brain metastases). She has no other financial relationships or interests to disclose. Dr. Shyr is an Independent Data Monitoring Committee member (statistical consultant) for Roche, Janssen, Novartis, and Aduro. He has no other financial relationships or interests to disclose. Dr. Smith serves as a consultant for Genentech, Celgene, Portola Pharmaceuticals, Pharmacyclics, TG Therapeutics, Abbvie, Juno Therapeutics, and Gilead. She has also received honoraria from Amgen, Janssen, and Celgene (she gave internal educational talks to their sales force). She has no other financial relationships or interests to disclose. Dr. Sood has no financial relationships or interests to disclose. Dr. Sturgis has no financial relationships or interests to disclose. Dr. Terry has no financial relationships or interests to disclose. Dr. Tevaarwerk has no financial relationships or interests to disclose. Dr. Tighiouart has no financial relationships or interests to disclose. Dr. Toll has no financial relationships or interests to disclose. Dr. Wick serves as a Board member for German Cancer Aid (reviews grant applications) and a consultant for Roche on bevacizumab development (AVAglio trial steering committee). He has received academic grants for trials from Boehringer Ingelheim, MSD, Apogenix, Roche, and Pfizer. He has also received honoraria from Roche, MSD, and Bristol-Myers Squibb, and travel to ASCO 2013-2015 paid by Roche. He has no other financial relationships or interests to disclose. Dr. Wisinski is a grantee of Daiichi Sankyo (PI on grant funding correlative studies for a clinical trial). She has no other financial relationships or interests to disclose. Dr. Zadeh has no financial relationships or interests to disclose. |
京公网安备 11010802027423号